Children's Hospital Association submitted comments on the cell and gene therapy request for information (RFI) from Sen. Bill Cassidy (R-La.), ranking member of the Senate Health, Education, Labor, and Pensions (HELP) Committee. Our response highlights the need to ensure children’s equitable access to these therapies and a strong national framework for payment and oversight.
CHA Response to Cell and Gene Therapy RFI
Cell and gene therapies have the potential to address unmet pediatric medical needs, reduce the need for costly chronic care, and help address health disparities.
Related Content
CHA Commends House Passage of Bipartisan Bill to Streamline Access to Pediatric Care
3 Keys to More Equitable Tracheostomy Patient Care
High-Cost Therapies for Pediatrics
CHA Commends House Passage of Bipartisan Bill to Streamline Access to Pediatric Care
Accelerating Kids’ Access to Care Act improves children’s ability to receive critical out-of-state care
Sep. 18, 2024
3 Keys to More Equitable Tracheostomy Patient Care
How to help caregivers confronted with an avalanche of challenges in tracheostomy care at home.
Sep. 16, 2024
High-Cost Therapies for Pediatrics
Pediatric HCTs are innovative and lifesaving or life-altering treatments for children with chronic, rare, and complex conditions.
Sep. 06, 2024
